The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The impact of comorbidity on mortality in multiple myeloma : a Danish nationwide population-based study. / Gregersen, Henrik; Vangsted, Annette Juul; Abildgaard, Niels; Andersen, Niels Frost; Pedersen, Robert Schou; Frølund, Ulf Christian; Helleberg, Carsten; Broch, Bettina; Pedersen, Per Trøllund; Gimsing, Peter; Klausen, Tobias Wirenfeldt.
I: Cancer Medicine, Bind 6, Nr. 7, 06.2017, s. 1807-1816.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The impact of comorbidity on mortality in multiple myeloma
T2 - a Danish nationwide population-based study
AU - Gregersen, Henrik
AU - Vangsted, Annette Juul
AU - Abildgaard, Niels
AU - Andersen, Niels Frost
AU - Pedersen, Robert Schou
AU - Frølund, Ulf Christian
AU - Helleberg, Carsten
AU - Broch, Bettina
AU - Pedersen, Per Trøllund
AU - Gimsing, Peter
AU - Klausen, Tobias Wirenfeldt
N1 - © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2017/6
Y1 - 2017/6
N2 - To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.
AB - To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Case-Control Studies
KW - Comorbidity
KW - Denmark/epidemiology
KW - Female
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Male
KW - Melphalan/administration & dosage
KW - Middle Aged
KW - Mortality
KW - Multiple Myeloma/diagnosis
KW - Odds Ratio
KW - Population Surveillance
KW - Prognosis
KW - Proportional Hazards Models
KW - Registries
KW - Risk Factors
KW - Transplantation Conditioning
KW - Young Adult
U2 - 10.1002/cam4.1128
DO - 10.1002/cam4.1128
M3 - Journal article
C2 - 28639741
VL - 6
SP - 1807
EP - 1816
JO - Cancer Medicine
JF - Cancer Medicine
SN - 2045-7634
IS - 7
ER -
ID: 195011220